Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
THERAPICON SRL
| THERAPICON SRL Patent applications | ||
| Patent application number | Title | Published |
|---|---|---|
| 20100029579 | ANTIVIRAL COMPOUNDS - The invention provides a new class of compounds exhibiting an inhibitory effect on neuraminidase (NA), hemagglutinin (HA) and structural M | 02-04-2010 |
| 20100028322 | ANTIMETASTATIC EFFECT ON HUMAN CELL DISORDERS - Use of recombinant human lysozyme in the preparation of a medicament for controlling life-threatening diseases associated with abnormal cell proliferation and migration, such as cancer metastasis, by administering to a subject in need thereof therapeutically effective doses of recombinant human lysozyme to elicit said antiproliferative and antimetastatic effects. | 02-04-2010 |
| 20090035260 | ENHANCED NASAL COMPOSITION OF ACTIVE PEPTIDE - A pharmaceutical composition has a therapeutically effective amount of at least one of: a pharmaceutically active nasal peptide, its pharmaceutically acceptable salt and its peptidic fragment. The composition also contains an absorbefacient effective amount of THAM in a pharmaceutically acceptable, aqueous liquid diluent or carrier. The composition is provided in a convenient form for nasal administration. In one embodiment, the peptidic fragment may be selected physiologically active lymphokines and monokines, peptidic enzymes, proteic vaccines, peptidic toxoids and personalized proteins derived from genoma. In another embodiment, the peptidic fragment may be selected from the peptide hormones and hormone antagonists buserelin, desmopressin, vasopressin, angiotensin, felypressin, octreotide, somatropin, thyrotropin (TSH), somatostatin, gosereline, thryptorelin and insulin selected from the group consisting of cow and pig, synthetic and recombinant. | 02-05-2009 |
| 20080286257 | Compounds for Use in Treating Abnormal Cell Proliferation, and Methods of Producing Same - The invention relates to the modification of recombinant human lysozyme from genetic engineering (rHLys) by reacting with activated polyethylene glycols (PEGs), which are partially binding or saturating with typical linkers one or more out of the six free amino groups of the five lysines (K) present in the rHLys chain. The resulting conjugate compounds of the invention (PEG-rHLys) and their addition salts, inhibit the abnormal cell proliferation and show remarkable antiproliferative and antimetastatic effects. The invention relates also to the use of the new compounds in the preparation of pharmaceutical compositions for treating a disease associated with abnormal cell proliferation, including cancer, by administering said conjugates to a subject in need thereof. | 11-20-2008 |